McKesson Corporation ( MCK Quick Quote MCK - Free Report) recently announced that its independent specialty pharmacy specializing in oncology and rare disease areas, Biologics by McKesson, was selected by Aadi Bioscience as a specialty pharmacy provider for FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound). The therapy is a mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
FYARRO was approved by the FDA in November for the treatment of PEComa.
The availability of FDA-approved drug is expected to significantly solidify McKesson’s foothold in the global cancer treatment space and boost its U.S. Pharmaceutical business.
Significance of the Availability
Per management, patients with advanced malignant PEComa have limited treatment options and face a poor prognosis. Management also feels that the availability of the drug via its Biologics specialty pharmacy will likely provide a treatment option to these patients.
Industry Prospects Per a report by Straits Research, the global oncology cancer drugs market was valued at $148,050.6 million in 2021 and is anticipated to reach $288,636.6 million by 2030 at a CAGR of 7.7%. Factors like the rise in the incidence of various cancer conditions and the growing popularity of advanced therapies (such as biological and targeted drug therapies) are expected to drive the market.
Given the market potential, the recent drug availability is expected to strengthen McKesson’s position in the global oncology care space.
This month, McKesson announced that Biologics by McKesson has been selected by Rigel Pharmaceuticals as one of two specialty pharmacies in a limited distribution network for REZLIDHIATM (olutasidenib).
Also, this month, Biologics by McKesson was selected by Mirati therapeutics as one of two specialty pharmacies in a limited distribution network for KRAZATI (adagrasib).
Last month, McKesson announced its second-quarter fiscal 2023 results, where it recorded a solid uptick in the overall top line. This was primarily driven by growth in the U.S. Pharmaceutical segment resulting from increased specialty product volumes (including retail national account customers) and market growth.
Shares of the company have gained 58.6% in the past year against the
industry’s 11% decline and the S&P 500's 19.5% fall. Image Source: Zacks Investment Research Zacks Rank & Key Picks
Currently, McKesson carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are
Exact Sciences Corporation ( EXAS Quick Quote EXAS - Free Report) , ShockWave Medical, Inc. ( SWAV Quick Quote SWAV - Free Report) and Merit Medical Systems, Inc. ( MMSI Quick Quote MMSI - Free Report) .
Exact Sciences, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 27.5%. EXAS’ earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed the same in one, the average beat being 0.6%.
You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Exact Sciences has lost 31.9% compared with the
industry’s 22.5% decline in the past year.
ShockWave Medical, carrying a Zacks Rank #2 at present, has an estimated growth rate of 22.2% for 2023. SWAV’s earnings surpassed estimates in all the trailing four quarters, the average beat being 146.1%.
ShockWave Medical has gained 17.4% against the
industry’s 28.7% decline over the past year.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%.
Merit Medical has gained 11.2% against the industry’s 11% decline over the past year.